Heart Failure Flashcards

1
Q

define as a complex clinical syndrome that results from structural or functional impairment of ventricular filling or ejection of blood, which in turn leads to the cardinal clinical symptoms of dyspnea and fatigue and signs of HF, namely edema and rales.

A

Heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The overall prevalence of HF in the adult population in developed countries is

A

2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HF prevalence
follows an exponential pattern, rising with age, and affects

A

6–10% of people over age 65.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

True or false:

Although the relative incidence of HF is lower in women than in men, women constitute at least one-half the cases of HF because of their longer life expectancy.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In industrialized countries, _____ has become the predominant cause in men and women and is responsible for 60–75% of cases of HF.

A

coronary artery disease (CAD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Hypertension contributes to the development of HF in how many percent of patients, including most patients with CAD.

A

75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Etiology of heart failure with depressed ejection fraction <40%

A
CAD
HTN
Obstructive Valvular disease
Regurgitation valvular disease 
Intracardiac shunting
Extracardiac shunting 
Col pulmonale
Pulmonary vascular disorder 
Non-ischemic dilated cardiomyopathy 
Toxic/drug induced damage
Chaga's disease
Chronic bradycardia or tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Preserved ejection fraction causes of HF

A
Secondary Hypertension 
Hypertrophic cardiomyopathy 
Restrictive cardiomyopathy 
Amyloidoisis
Sarcoidosis 
Hemochromatosis fibrosis
Endomyocardial disorders
Aging
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

High output states causes of HF

A

Thyrotoxicosis (metabolic d/o)
Nutritional d/o (beriberi)
Excessive blood flow requirement
(Chronic anemia and systemic AV shunting)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

____ emerging as the single most common cause of HF.

A

CAD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Community-based studies indicate that _____ of patients die within 1 year of diagnosis and ____ die within 5 years, mainly from worsening HF or as a sudden event (probably because of a ventricular arrhythmia).

A
  1. 30–40%

2. 60–70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

patients with symptoms at rest (New York Heart Association [NYHA] class IV) have a _____ annual mortality rate, whereas patients with symptoms with moderate activity (NYHA class II) have an annual mortality rate of ____

A
  1. 30–70%

2. 5–10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Major determinant of Preload or VEDV

VENTRICULAR END DIASTOLIC VOLUME

A

Total blood volume
Distribution of blood volume
Atrial contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Major determinants

of AFTERLOAD

A

Systemic vascular resistance
Elasticity of arterial tree
Arterial blood volume
Ventricular wall tension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MECHANISM OF HFPEF

A

Diastolic dysfunction
Increased vascular stiffness
Impaired renal function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cardinal symptoms of HF

A

Fatigue
And
Shortness of breath

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Most important mechanism of HF

A

Pulmonary congestion which activates juxtacapillary J receptors that stimulates a rapid shallow breathing (cardiac dyspnea)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Etiologies of heart failure with preserved ejection fraction (>40-50%):

A
Hypertrophic CM
Hypertension 
Restrictive cardiomyopathy 
Infiltrative d/o (amyloidosis, sarcoidosis)
Storage diseases (hemochromatosis)
Fibrosis, endomyocardial disorders
Aging
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Etiologies of heart failure with high output states:

A

Metabolic disorders: thyrotoxicosis
Nutritional disorders: BERI BERI
Excessive Blood flow requirements: systemic AV shunting, chronic anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Major cause of HF in AFRICA AND ASIA esp in the young

A

RHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Known causes of DILATED CMP

A
Prior viral infection 
Toxin exposure (ALCOHOL, CHEMO)
Genetic defect in cytoskeleton, muscular dystrophy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Most forms of familial dilated CMP

A

Autosomal dominant inheritance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Mechanisms that explains dyspnea in heart failure :

A
Pulmonary congestion 
Decreased pulmonary compliance 
Increased airway resistance
Respiratory muscle or diaphragm fatigue
Anemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Mechanism: redistribution of fluid from the splanchnic circulation and lower extremities INTO the central circulation during recumbency => increased PCWP

A

Orthopnea

25
Q

Mechanism: increased pressure in the bronchial arteries leading to airway compression + interstitial pulmonary edema causing increased airway resistance

A

PND

usually 1-3hrs after retiring

26
Q

Periodic respiration or cyclic respiration sec to increased sensitivity of the respiratory center to arterial PCO2 and increased circulatory time

A

Cheyne stokes respiration

27
Q

“Routine” lab test for new onset HF or chronic heart failure:

A
CBC
ELECTROLYTES 
BUN CREA
HEPATIC ENZYMES 
UA
28
Q

Gold standard for assessing LV mass and volume

A

MRI

accurate evaluation of LV structure and causes of HF (amyloidosis,hemochromatosis, CMP - HRPEF)

29
Q

Most useful index of LV dysfunction

A

Ejection fraction (Normal >/=50%)

30
Q

Increased levels of PRO BNP

A
Increased AGE
Renal impairment
Women 
Right heart failure from any cause
Use of ARNI
31
Q

Pulmary heart disease,

altered “RV” structure and or function in chronic lung disease and triggered by PULMONARY HYPERTENSION

A

Col pulmonale

32
Q

Common mechanism of col pulmonale

A

Pulmonary hypertension
Inc right ventricular AFTERLOAD
RV DILATION AND HYPERTROPHY
ALTERED RV FX

33
Q

Signs of CHRONIC COL PULMONALE

A

TR MURMUR
S3 gallop
RV HEAVE

34
Q

ECG in severe pulmonary hypertension

A

P pulmonale
RAD
RVH

35
Q

Confirms diagnosis of pulmonary hypertension

A

Right heart catherization

36
Q

Parameters associated with worse prognosis

A

Bun > 43mg/dL
SBP <115 mmHg
CREA > 2.75mg/dL
ELEVATED TROPONIN

37
Q

Stabilizing hemodynamics using PULMONARY ARTERY CATHETER is NOT recommended unless

A

Hypotension
Poor response to DIURETICS
SSX of LOW CO

38
Q

Management for typical ADHF that is hypertensive

A

VASODILATORS

39
Q

Management for typical ADHF that is NORMOTENSIVE (volume overload)

A

DIURETICS

40
Q

Cornerstone therapy for HFREF

A

Acei and BB

41
Q

Benefit of ACE-I and BB extends to NYHA Class

A

Class IIIB - IV

42
Q

Treatment for PULMONARY EDEMA ADHF

A

Opiates
VASODILATORS
DIURETICS
O2 and Noninvasive ventilation

43
Q

Inotropic therapy for ADHF which increased CAMP and cytoplasmic calcium

A

Dobutamine (b1 agonist)

Milrinone (PDE INHIBITOR)

44
Q

Indication for Inotropic therapy for ADHF

A

As bridge therapy ( to LV assist device support or transplant)
Palliation in end stage HF

45
Q

Beta blockers dose dependent improvement and reduction in mortality and hospitalization is restricted to

A

CBM
Carvedilol
Bisoprolol
Metoprolol succinate

46
Q

Mineralocorticoid antagonist that is selective for NYHA II and post MI HF

A

Eplerenone

47
Q

Mineralocorticoid antagonist that is non-selective, NYHA III-IV

A

SPIRONOLACTONE

48
Q

Neurohormonal escape Strategy is ACEI + BB, ARB + BB or ACEI + ARBS if BB INTOLERANT, HOWEVER IF SYMPTOMATIC NYHA II -IV May add

A

Aldosterone antagonist

49
Q

Substitute to acei and ARBs if intolerable (hyperkalemia and renal insufficiency) combined arterial dilator and about dilator, with benefits for African Americans

A

Hydralazine and nitrates

50
Q

Trial for sacubitril - Valsartan (ARNI improves survival compared to ACEI alone)

A

PARADIGM HF TRIAL

51
Q

Inhibitor of funny channels If in the SA NODE which slows HR WITHOUT a negative inotropic effect (SHIFT TRIAL)
Indicated in symptomatic px despite Acei, bb and aldo ant with residual hr>70bpm

A

IVABRADINE

52
Q

True or false

In DIG trial: there is decreased HF HOSPITALIZATION but no reduction in mortality , no improvement in QOL AND INCREASED mortality rate and hospitalization in W>M

A

TRUE

53
Q

Use as initial treatment of HF to achieve volume control prior to neurohormonal therapy

A

Oral diuretics

54
Q

Use to DECREASE BP in HF

A

Second generation CCB AMLODIPINE AND FELODIPINE

DO NOT USE 1st gen and NON DHP (diltiazem and verapamil)

55
Q

Treatment of anemia in HF sec to iron deficient, dysregulation of iron metabolism and occult gi bleeding

A

IV IRON ( iron sucrose and carboxymaltose)

56
Q

Treatment of AF in HF

A

AMIODARONE

DOFETILIDE

57
Q

Dm therapy that DECREASES CV MORTALITYand hospitalization in HF

A

EMPAGLIFLOZIN (SGLT2 inhibitor)

58
Q

Surgical therapy for px with ischemic cm with multi vessel CAD in HF

A

CABG

59
Q

Alterations in Left Ventricular Chamber Geometry

A

Left ventricular (LV) dilation
Increased LV sphericity
LV wall thinning
Mitral valve incompetence